Ampio Pharmaceuticals reported cash and cash equivalents of $17.1 million. They also reported a net loss of $3.628 million, or $0.02 per share.

Ampio Pharmaceuticals reported a net loss of $3.556 million for the second quarter of 2021. The company's cash and cash equivalents totaled $20.5 million as of June 30, 2021, compared to $17.3 million on December 31, 2020.

Ampio Pharmaceuticals reported its annual financial results for the year ended December 31, 2020. The company's cash and cash equivalents totaled $17.3 million, and research and development expenditures were $9.2 million.

Ampio Pharmaceuticals reported its Q3 2020 financial results, with a net loss of $3.4 million. The company had $9.4 million in cash and cash equivalents as of September 30, 2020. The company provided updates on its COVID-19 platform and OAK clinical trial.